Federated Hermes’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.99M Sell
39,928
-123
-0.3% -$7.9K ﹤0.01% 942
2026
Q1
$2.26M Buy
40,051
+1,154
+3% +$75.2K ﹤0.01% 950
2025
Q4
$3.12M Sell
38,897
-7,207
-16% -$484K 0.01% 873
2025
Q3
$2.25M Buy
46,104
+43,042
+1,406% +$2.66M ﹤0.01% 905
2025
Q2
$228K Buy
3,062
+72
+2% +$4.77K ﹤0.01% 1468
2025
Q1
$190K Sell
2,990
-564
-16% -$38.4K ﹤0.01% 1493
2024
Q4
$277K Sell
3,554
-436
-11% -$35K ﹤0.01% 1433
2024
Q3
$321K Sell
3,990
-29,358
-88% -$2.37M ﹤0.01% 1408
2024
Q2
$2.76M Sell
33,348
-2,559
-7% -$225K 0.01% 850
2024
Q1
$3.06M Sell
35,907
-3,185
-8% -$250K 0.01% 832
2023
Q4
$3.34M Sell
39,092
-1,887
-5% -$163K 0.01% 817
2023
Q3
$3.67M Sell
40,979
-896
-2% -$80K 0.01% 780
2023
Q2
$3.57M Buy
41,875
+34,389
+459% +$2.91M 0.01% 786
2023
Q1
$619K Sell
7,486
-364
-5% -$29.5K ﹤0.01% 1340
2022
Q4
$617K Sell
7,850
-1,614
-17% -$130K ﹤0.01% 1294
2022
Q3
$700K Sell
9,464
-1,827
-16% -$131K ﹤0.01% 1236
2022
Q2
$736K Sell
11,291
-451,295
-98% -$26.7M ﹤0.01% 1257
2022
Q1
$29.2M Buy
462,586
+320,184
+225% +$17.4M 0.07% 353
2021
Q4
$7.55M Buy
142,402
+132,391
+1,322% +$8.07M 0.01% 728
2021
Q3
$707K Buy
10,011
+3,879
+63% +$245K ﹤0.01% 1400
2021
Q2
$409K Sell
6,132
-3,959
-39% -$280K ﹤0.01% 1554
2021
Q1
$1.12M Sell
10,091
-383
-4% -$47.4K ﹤0.01% 1326
2020
Q4
$1.24M Sell
10,474
-44,410
-81% -$4.78M ﹤0.01% 1248
2020
Q3
$4.79M Sell
54,884
-21,670
-28% -$1.89M 0.01% 741
2020
Q2
$6.86M Buy
76,554
+60,888
+389% +$6.15M 0.02% 630
2020
Q1
$1.56M Sell
15,666
-80,169
-84% -$8.69M ﹤0.01% 969
2019
Q4
$11M Buy
95,835
+9,820
+11% +$1.19M 0.02% 572
2019
Q3
$10.8M Buy
86,015
+69,200
+412% +$8.78M 0.03% 548
2019
Q2
$2.02M Sell
16,815
-5,658
-25% -$557K ﹤0.01% 1051
2019
Q1
$1.97M Sell
22,473
-105,219
-82% -$9.57M ﹤0.01% 1055
2018
Q4
$12.8M Sell
127,692
-37,042
-22% -$3.89M 0.03% 416
2018
Q3
$18.9M Sell
164,734
-12,085
-7% -$1.25M 0.04% 371
2018
Q2
$15.9M Buy
176,819
+31,551
+22% +$2.66M 0.05% 316
2018
Q1
$10.6M Buy
145,268
+144,102
+12,359% +$9.89M 0.03% 403
2017
Q4
$68K Sell
1,166
-31
-3% -$1.63K ﹤0.01% 1634
2017
Q3
$54K Sell
1,197
-77
-6% -$3.2K ﹤0.01% 1636
2017
Q2
$50K Buy
1,274
+16
+1% +$657 ﹤0.01% 1660
2017
Q1
$51K Sell
1,258
-182
-13% -$7.11K ﹤0.01% 1621
2016
Q4
$58K Sell
1,440
-151
-9% -$5.69K ﹤0.01% 1639
2016
Q3
$58K Sell
1,591
-295
-16% -$10.1K ﹤0.01% 1616
2016
Q2
$55K Sell
1,886
-214
-10% -$6.47K ﹤0.01% 1650
2016
Q1
$73K Hold
2,100
﹤0.01% 1606
2015
Q4
$68K Buy
+2,100
New +$68.1K ﹤0.01% 1631
2015
Q1
Sell
-173
Closed -$6K 2027
2014
Q4
$6K Sell
173
-12
-6% -$440 ﹤0.01% 1806
2014
Q3
$6K Sell
185
-1,572
-89% -$56.1K ﹤0.01% 1810
2014
Q2
$62K Sell
1,757
-864
-33% -$28.9K ﹤0.01% 1620
2014
Q1
$85K Buy
2,621
+2,124
+427% +$81.2K ﹤0.01% 1605
2013
Q4
$21K Buy
+497
New +$20.5K ﹤0.01% 1689

Other funds holding HAE

Federated Hermes's HAE Position: Q2 2026 in Review

Federated Hermes reduced its Haemonetics (HAE) stake by 0.31% in Q2 2026, selling an estimated $7.9K and leaving 39,928 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #942.

Federated Hermes first reported a position in HAE in Q4 2013 and has held it in 48 quarters since. The position peaked at $29.2M in Q1 2022. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Federated Hermes held 39,928 shares of Haemonetics worth $2.99M as of Q2 2026.
  • Federated Hermes sold 123 Haemonetics shares in Q2 2026, an estimated $7.9K.
  • Haemonetics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #942 holding.
  • Federated Hermes first reported a position in Haemonetics in Q4 2013 and has held it in 48 quarters since.
  • Federated Hermes's Haemonetics position peaked at $29.2M in Q1 2022.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.